Mesoblast (MESO) Long-Term Debt Issuances (2018)
Mesoblast recorded quarterly Long-Term Debt Issuances of $29.0 million in Q3 2018.
Mesoblast's Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $29.0 million for Q3 2018.
- In Q3 2018, Long-Term Debt Issuances changed N/A year-over-year to $29.0 million; the TTM figure through Jun 2023 stood at $29.0 million (changed N/A YoY), while the FY2022 annual figure was $51.9 million, changed N/A from the prior year.
- Long-Term Debt Issuances came in at $29.0 million for Q3 2018 at Mesoblast.
- In the past five years, Long-Term Debt Issuances ranged from a high of $29.0 million in Q3 2018 to a low of $29.0 million in Q3 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 28.95 Mn |
| Sep 30, 2018 | 28.95 Mn |